This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock ELTX vs. ABUS, PHAT, TYRA, BCYC, KROS, ARVN, FTRE, SEPN, SLDB, and REPLShould you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Arbutus Biopharma (ABUS), Phathom Pharmaceuticals (PHAT), Tyra Biosciences (TYRA), Bicycle Therapeutics (BCYC), Keros Therapeutics (KROS), Arvinas (ARVN), Fortrea (FTRE), Septerna (SEPN), Solid Biosciences (SLDB), and Replimune Group (REPL). These companies are all part of the "med - biomed/gene" industry. Elicio Therapeutics vs. Its Competitors Arbutus Biopharma Phathom Pharmaceuticals Tyra Biosciences Bicycle Therapeutics Keros Therapeutics Arvinas Fortrea Septerna Solid Biosciences Replimune Group Elicio Therapeutics (NASDAQ:ELTX) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment. Does the media refer more to ELTX or ABUS? In the previous week, Arbutus Biopharma had 2 more articles in the media than Elicio Therapeutics. MarketBeat recorded 2 mentions for Arbutus Biopharma and 0 mentions for Elicio Therapeutics. Arbutus Biopharma's average media sentiment score of 0.30 beat Elicio Therapeutics' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Elicio Therapeutics Neutral Arbutus Biopharma Neutral Do analysts recommend ELTX or ABUS? Elicio Therapeutics currently has a consensus price target of $13.00, suggesting a potential upside of 30.26%. Arbutus Biopharma has a consensus price target of $5.50, suggesting a potential upside of 64.42%. Given Arbutus Biopharma's higher probable upside, analysts plainly believe Arbutus Biopharma is more favorable than Elicio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elicio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of ELTX or ABUS? 35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 28.7% of Elicio Therapeutics shares are held by company insiders. Comparatively, 20.3% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better earnings and valuation, ELTX or ABUS? Elicio Therapeutics has higher earnings, but lower revenue than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElicio Therapeutics$2.30M69.43-$51.90M-$6.95-1.44Arbutus Biopharma$6.40M100.06-$69.92M-$0.41-8.16 Which has more risk and volatility, ELTX or ABUS? Elicio Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Is ELTX or ABUS more profitable? Elicio Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,196.64%. Elicio Therapeutics' return on equity of 0.00% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Elicio TherapeuticsN/A N/A -185.70% Arbutus Biopharma -1,196.64%-75.51%-55.81% SummaryArbutus Biopharma beats Elicio Therapeutics on 9 of the 15 factors compared between the two stocks. Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELTX vs. The Competition Export to ExcelMetricElicio TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$159.68M$3.05B$5.57B$9.50BDividend YieldN/A2.45%4.74%4.13%P/E Ratio-2.5517.9029.1324.33Price / Sales69.43290.20435.22175.21Price / CashN/A40.5624.4827.20Price / Book-9.698.588.535.75Net Income-$51.90M-$54.98M$3.24B$264.99M Elicio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELTXElicio Therapeutics1.8772 of 5 stars$9.98+1.7%$13.00+30.3%+97.2%$159.68M$2.30M-2.55N/AABUSArbutus Biopharma2.1867 of 5 stars$3.35+1.4%$5.50+64.4%-12.4%$642.58M$6.17M-8.1890Positive NewsUpcoming EarningsPHATPhathom Pharmaceuticals2.6868 of 5 stars$9.00+4.4%$17.50+94.5%-27.5%$629.97M$55.25M-1.72110Upcoming EarningsTYRATyra Biosciences1.6378 of 5 stars$11.44+2.2%$30.83+169.5%-48.5%$611.07MN/A-7.0620Upcoming EarningsShort Interest ↑BCYCBicycle Therapeutics3.5851 of 5 stars$8.72+2.3%$24.22+177.9%-68.4%$601.09M$35.28M-2.76240Positive NewsUpcoming EarningsKROSKeros Therapeutics2.5958 of 5 stars$14.59+0.7%$30.56+109.5%-70.9%$592.36M$3.55M-81.02100News CoveragePositive NewsUpcoming EarningsARVNArvinas2.8229 of 5 stars$7.98+6.6%$20.29+154.4%-71.3%$583.04M$263.40M-12.10420Upcoming EarningsFTREFortrea4.1471 of 5 stars$6.32-0.6%$14.00+121.4%-79.4%$574.68M$2.70B-0.7215,500Upcoming EarningsAnalyst UpgradeGap UpSEPNSepterna1.3811 of 5 stars$12.86+0.8%$26.75+108.1%N/A$571.26M$1.08M0.00N/ASLDBSolid Biosciences2.8921 of 5 stars$7.24+2.3%$15.10+108.7%-13.0%$563.65M$8.09M-2.43100REPLReplimune Group4.6783 of 5 stars$7.47+99.1%$7.67+2.7%-24.8%$563.42MN/A-2.36210Gap DownHigh Trading Volume Related Companies and Tools Related Companies ABUS Competitors PHAT Competitors TYRA Competitors BCYC Competitors KROS Competitors ARVN Competitors FTRE Competitors SEPN Competitors SLDB Competitors REPL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELTX) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
